Innovative Medicine was Johnson & Johnson’s largest segment in fiscal 2023, bringing in $27.79B of $42.70B (65%).
| Segment | FY 2009 | FY 2009 | FY 2009 | FY 2010 | FY 2010 | FY 2010 | FY 2011 | FY 2011 | FY 2011 | FY 2012 | FY 2012 | FY 2012 | FY 2013 | FY 2013 | FY 2013 | FY 2014 | FY 2014 | FY 2014 | FY 2015 | FY 2015 | FY 2015 | FY 2016 | FY 2016 | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2022 | FY 2022 | FY 2022 | FY 2023 | FY 2023 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $25.74B | $26.63B | $26.43B | $26.83B | $27.46B | $27.79B | |||||||||||||||||||||||||||||||||
| Pharmaceutical | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Medtech | $13.94B | $13.80B | $13.56B | $14.96B | $15.58B | $14.92B | |||||||||||||||||||||||||||||||||
| Med Devices | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Medical Devices | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Medical Devices & Diagnostics | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Consumer | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Total | $39.68B | $40.43B | $39.99B | $41.79B | $43.04B | $42.70B |
Johnson & Johnson brought in $42.70B from its two segments in fiscal 2023, the year ended October 1, 2023. That was down 0.8% from $43.04B in fiscal 2023. Innovative Medicine was the largest at $27.79B (65.1%), ahead of Medtech at $14.92B (34.9%).
Compared with fiscal 2023, Innovative Medicine grew 1.2% to $27.79B, while Medtech fell 4.2% to $14.92B.
United States was Johnson & Johnson’s largest region in fiscal 2017, bringing in $79.73B of $152.90B (52%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Segments | — | — | $143.78B | — | |||||
| United States | $69.56B | $71.37B | — | $79.73B | |||||
| U S | — | — | — | — | |||||
| Europe | $37.89B | $31.99B | — | $34.25B | |||||
| Asia-Pacific, Africa | $26.88B | $24.69B | — | $26.84B | |||||
| Segment, Geographical, Groups Of Countries, Group Two | — | — | — | — | |||||
| Segment Geographical Groups Of Countries Group Two | — | — | — | — | |||||
| Western Hemisphere Excluding U.S | $14.32B | $12.09B | — | $12.08B | |||||
| Western Hemisphere, Excluding U.S | — | — | — | — | |||||
| Segment, Geographical, Groups Of Countries, Group One | — | — | — | — | |||||
| Segment Geographical Groups Of Countries Group | — | — | — | — | |||||
| Total | $148.66B | $140.15B | $143.78B | $152.90B |
Johnson & Johnson brought in $152.90B from its four regions in fiscal 2017, the year ended December 31, 2017. Johnson & Johnson regrouped these regions after fiscal 2017, so the total does not compare directly with that year's $143.78B. United States was the largest at $79.73B (52.1%), ahead of Europe at $34.25B (22.4%) and Asia-Pacific, Africa at $26.84B (17.6%). The remaining region, Western Hemisphere Excluding U.S, brought in $12.08B.
From fiscal 2014 to 2017, combined revenue from these regions grew from $148.66B to $152.90B, a compound annual growth rate of 0.9%. United States' share of the total rose from 46.8% to 52.1%.
Johnson & Johnson stopped reporting Operating Segments as a separate region after fiscal 2017, when it brought in $143.78B.
Johnson & Johnson (JNJ) reports its revenue by segment and by geography. In fiscal 2023, Innovative Medicine was its largest segment, bringing in $27.79B (65.1% of the total), followed by Medtech at $14.92B (34.9%).
Innovative Medicine was Johnson & Johnson's largest segment in fiscal 2023, bringing in $27.79B, or 65.1% of the $42.70B total across its two segments.
United States was Johnson & Johnson's largest region in fiscal 2017, bringing in $79.73B, or 52.1% of the $152.90B total across its four regions.
Every figure comes from Johnson & Johnson's annual financial filings, as reported. Each line keeps the name Johnson & Johnson gives it, and years follow its fiscal calendar.
Johnson & Johnson's revenue by segment goes back to fiscal 2009, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.